Kazia Therapeutics Limited Quick Ratio (KZIA) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kazia Therapeutics Limited  (NASDAQ: KZIA)

Kazia Therapeutics Limited's Quick Ratio

KZIA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Kazia Therapeutics Limited's Cash & cash equivalent grew by 52.14 % in the Q4 2025 sequentially, faster than Current Liabilities, this led to improvement in Kazia Therapeutics Limited's Quick Ratio to 0.31, Quick Ratio remained below Kazia Therapeutics Limited average.

Within Major Pharmaceutical Preparations industry 401 other companies have achieved higher Quick Ratio than Kazia Therapeutics Limited in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 2575, from total ranking in the third quarter 2025 at 4055.

Explain Quick Ratio?
How much Cash & cash equivalents KZIA´s has?
What are KZIA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KZIA Quick Ratio (Jun 30 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Jun 30 2024)
Q4
Y / Y Current Liabilities Change -20.37 % -46.18 % -45.52 % -45.52 % 133.28 %
Y / Y Cash & cash equivalent Change 292.72 % 158.14 % 158.13 % 162.22 % -78.89 %
Quick Ratio MRQ 0.31 0.3 0.2 0.31 0.06
KZIA's Total Ranking # 2575 # 4055 # # #
Seq. Current Liabilities Change 47.97 % -32.42 % 0 % -20.37 % 0 %
Seq. Cash & cash equivalent Change 52.14 % -0 % -34.27 % 292.72 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 402
Healthcare Sector # 757
Overall Market # 2575


Quick Ratio Statistics
High Average Low
3.31 1.51 0.06
(Jun 30 2021)   (Jun 30 2024)




Financial Statements
Kazia Therapeutics Limited's Current Liabilities $ 14 Millions Visit KZIA's Balance sheet
Kazia Therapeutics Limited's Cash & cash equivalent $ 4 Millions Visit KZIA's Balance sheet
Source of KZIA's Sales Visit KZIA's Sales by Geography


Cumulative Kazia Therapeutics Limited's Quick Ratio

KZIA's Quick Ratio for the trailling 12 Months

KZIA Quick Ratio

 (Jun 30 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -40.55 % -28.06 % -3.05 % 59.33 % 200.32 %
Y / Y Cash & cash equivalent TTM Growth 189.42 % 22.53 % -18.12 % -44.79 % -71.51 %
Quick Ratio TTM 0.28 0.2 0.15 0.1 0.06
Total Ranking TTM # 3337 # 3662 # # #
Seq. Current Liabilities TTM Growth -6.51 % -12.86 % -15.63 % -13.52 % 13.13 %
Seq. Cash & cash equivalent TTM Growth 29.01 % 18.59 % 22.83 % 54.02 % -45.38 %

Quick ratio ranking by company, industry and sector >> Back to KZIA Financial Strength Comparisons >> Go to Compare KZIA Quick Ratio to its Competitors

On the trailing twelve months basis KZIA Cash & cash equivalent more than doubled by 292.72 % in Q4 2025 year on year, while Current Liabilities soared to $14 millions, this led to increase in in Kazia Therapeutics Limited's Quick Ratio to 0.28, Quick Ratio remained below KZIA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 426 other companies have achieved higher Quick Ratio than Kazia Therapeutics Limited. While Quick Ratio overall ranking has improved so far to 3337, from total ranking during the twelve months ending third quarter 2025 at 3662.

Explain Quick Ratio?
How much Cash & cash equivalents KZIA´s has?
What are KZIA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 427
Healthcare Sector # 885
Within the Market # 3337


trailing twelve months Quick Ratio Statistics
High Average Low
3.31 1.88 0.06
(Jun 30 2021)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Beyondspring Inc   0.84 $ 9.544  Millions$ 11.423  Millions
Legend Biotech Corporation  0.83 $ 266.586  Millions$ 321.814  Millions
Durect Corp  0.82 $ 6.502  Millions$ 7.893  Millions
Hyperion Defi inc   0.82 $ 8.420  Millions$ 10.311  Millions
Os Therapies Incorporated  0.81 $ 2.802  Millions$ 3.458  Millions
Incannex Healthcare Inc  0.81 $ 15.039  Millions$ 18.590  Millions
Fibrobiologics Inc   0.81 $ 8.845  Millions$ 10.964  Millions
Rein Therapeutics Inc   0.74 $ 5.722  Millions$ 7.694  Millions
Lifevantage Corp  0.74 $ 20.201  Millions$ 27.217  Millions
Assertio Holdings inc   0.74 $ 98.183  Millions$ 132.529  Millions
Grace Therapeutics Inc  0.73 $ 1.918  Millions$ 2.618  Millions
Jupiter Neurosciences Inc   0.73 $ 1.878  Millions$ 2.582  Millions
Indaptus Therapeutics Inc   0.73 $ 6.158  Millions$ 8.478  Millions
Azitra Inc   0.72 $ 1.046  Millions$ 1.452  Millions
Actuate Therapeutics Inc   0.71 $ 6.493  Millions$ 9.201  Millions
Cumberland Pharmaceuticals Inc   0.68 $ 16.087  Millions$ 23.586  Millions
Eton Pharmaceuticals Inc   0.66 $ 25.379  Millions$ 38.596  Millions
Novo Nordisk A  0.65 $ 2,908.325  Millions$ 4,449.808  Millions
Neurosense Therapeutics Ltd  0.65 $ 0.709  Millions$ 1.093  Millions
Scisparc Ltd  0.63 $ 1.545  Millions$ 2.463  Millions
Xeris Biopharma Holdings Inc   0.62 $ 59.285  Millions$ 95.171  Millions
Biolinerx Ltd   0.59 $ 7.189  Millions$ 12.123  Millions
Ascendis Pharma A  0.58 $ 691.961  Millions$ 1,197.718  Millions
Galapagos Nv  0.57 $ 98.412  Millions$ 171.207  Millions
Jazz Pharmaceuticals Plc  0.57 $ 1,189.880  Millions$ 2,071.205  Millions
Johnson and Johnson  0.57 $ 18,880.000  Millions$ 33,357.000  Millions
Tuhura Biosciences Inc   0.56 $ 8.513  Millions$ 15.172  Millions
Genprex Inc   0.55 $ 1.347  Millions$ 2.436  Millions
Decoy Therapeutics Inc   0.54 $ 0.795  Millions$ 1.482  Millions
Verrica Pharmaceuticals Inc   0.53 $ 15.396  Millions$ 29.222  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.